Fine‐mapping reveals novel alternative splicing of the dopamine transporter
暂无分享,去创建一个
G. Kirov | M. O’Donovan | P. Sullivan | M. Owen | D. Lewis | D. Toncheva | D. Ruderfer | M. Talkowski | A. J. Lopez | Jeffrey K. Yao | F. Miyajima | S. Leonard | K. Prasad | V. Nimgaonkar | P. Papasaikas | K. L. McCann | Michael Chen | L. McClain | M. Bamne | J. Wood | K. Chowdari | A. Watson | L. Georgieva | H. Mansour | Pramod Thomas | J. Quinn | D. Lewis | K. McCann
[1] M. Talkowski,et al. Functional analysis of upstream common polymorphisms of the dopamine transporter gene. , 2010, Schizophrenia bulletin.
[2] E. Bramon,et al. Altered effect of dopamine transporter 3'UTR VNTR genotype on prefrontal and striatal function in schizophrenia. , 2009, Archives of general psychiatry.
[3] P. Visscher,et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder , 2009, Nature.
[4] Jianxin Shi,et al. Common variants on chromosome 6p22.1 are associated with schizophrenia , 2009, Nature.
[5] D. Geschwind,et al. Functional and Evolutionary Insights into Human Brain Development through Global Transcriptome Analysis , 2009, Neuron.
[6] Leonardo Fazio,et al. Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia. , 2009, Brain : a journal of neurology.
[7] J. Smoller,et al. Family based association study of pediatric bipolar disorder and the dopamine transporter gene (SLC6A3) , 2008, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[8] O. Mühlemann,et al. The meaning of nonsense. , 2008, Trends in cell biology.
[9] J. Fackenthal,et al. Aberrant RNA splicing and its functional consequences in cancer cells , 2008, Disease Models & Mechanisms.
[10] Michael Hiller,et al. Widespread and subtle: alternative splicing at short-distance tandem sites. , 2008, Trends in genetics : TIG.
[11] J. Lieberman,et al. Genomewide association for schizophrenia in the CATIE study: results of stage 1 , 2008, Molecular Psychiatry.
[12] Michael E Talkowski,et al. A network of dopaminergic gene variations implicated as risk factors for schizophrenia. , 2008, Human molecular genetics.
[13] M. Rieder,et al. The environmental genome project: reference polymorphisms for drug metabolism genes and genome-wide association studies. , 2008, Drug metabolism reviews.
[14] J. Gádoros,et al. Dopaminergic candidate genes in Tourette syndrome: Association between tic severity and 3′ UTR polymorphism of the dopamine transporter gene , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[15] M. Talkowski,et al. Dopamine genes and schizophrenia: case closed or evidence pending? , 2007, Schizophrenia bulletin.
[16] Silke Schmidt,et al. Interleukin 7 receptor α chain ( IL7R ) shows allelic and functional association with multiple sclerosis , 2007, Nature Genetics.
[17] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[18] G. Breen,et al. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment , 2007, Pharmacogenetics and genomics.
[19] J. Gallant,et al. RNA-Mediated Neuromuscular Disorders , 2007 .
[20] E. Fernandez-Egea,et al. Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait , 2007, Psychopharmacology.
[21] C. Colosimo,et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor , 2007, Journal of Neural Transmission.
[22] N. Richtand. Behavioral Sensitization, Alternative Splicing, and D3 Dopamine Receptor-Mediated Inhibitory Function , 2006, Neuropsychopharmacology.
[23] C. Thornton,et al. RNA-dominant diseases. , 2006, Human molecular genetics.
[24] J. Lieberman,et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. , 2006, The American journal of psychiatry.
[25] R. Murray,et al. A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] H. Steinhausen. Faculty Opinions recommendation of A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. , 2006 .
[27] T. Sotnikova,et al. Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. , 2006, CNS & neurological disorders drug targets.
[28] Ravinder Reddy,et al. Altered Glutathione Redox State in Schizophrenia , 2005, Disease markers.
[29] David Haussler,et al. Unusual Intron Conservation near Tissue-Regulated Exons Found by Splicing Microarrays , 2005, PLoS Comput. Biol..
[30] Gerome Breen,et al. A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. , 2006, Archives of general psychiatry.
[31] Nikolaos Koutsouleris,et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug–naive schizophrenic patients , 2006, European Archives of Psychiatry and Clinical Neuroscience.
[32] Ian H. Robertson,et al. Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: Sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype , 2005, Neuropsychologia.
[33] H. Vaitkevicius,et al. Dopamine neurons express multiple isoforms of the nuclear receptor nurr1 with diminished transcriptional activity , 2005, Journal of neurochemistry.
[34] Nicolas Peyret,et al. The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. , 2005, Journal of biomolecular techniques : JBT.
[35] S. Gabriel,et al. Efficiency and power in genetic association studies , 2005, Nature Genetics.
[36] C. Carlson,et al. Dopamine transporter (SLC6A3) 5′ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease , 2005, Pharmacogenetics & Genomics.
[37] L. Maquat,et al. Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. , 2005, Current opinion in cell biology.
[38] J. Pavía,et al. Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism , 2005, Psychopharmacology.
[39] M. Bannon,et al. Sp1 and Sp3 activate transcription of the human dopamine transporter gene , 2005, Journal of neurochemistry.
[40] S. Fuke,et al. Identification and characterization of the Hesr1/Hey1 as a candidate trans-acting factor on gene expression through the 3' non-coding polymorphic region of the human dopamine transporter (DAT1) gene. , 2005, Journal of biochemistry.
[41] A. Sampson,et al. Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia , 2005, The Journal of Neuroscience.
[42] D. Kupfer,et al. Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter , 2005, Annals of medicine.
[43] A. Krainer,et al. Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1 , 2004, Human mutation.
[44] G. Hutchins,et al. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia , 2004, Schizophrenia Research.
[45] P. Chen,et al. Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. , 2004, The American journal of psychiatry.
[46] S. Gallati,et al. The role of common single‐nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR Alleles , 2004, Human mutation.
[47] Ivan Nikolov,et al. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria , 2004, Biological Psychiatry.
[48] S. Cragg,et al. DAncing past the DAT at a DA synapse , 2004, Trends in Neurosciences.
[49] M. Garcia-Blanco,et al. Alternative splicing in disease and therapy , 2004, Nature Biotechnology.
[50] J. Sundsfjord,et al. 123I-β-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia , 2004, Psychopharmacology.
[51] D. Black. Mechanisms of alternative pre-messenger RNA splicing. , 2003, Annual review of biochemistry.
[52] Christopher J. Lee,et al. Alternative splicing in the nervous system: an emerging source of diversity and regulation , 2003, Biological Psychiatry.
[53] F. Limosin,et al. The A9 allele of the dopamine transporter gene is associated with delirium tremens and alcohol-withdrawal seizure , 2003, Biological Psychiatry.
[54] D L Black,et al. Alternative pre-mRNA splicing and neuronal function. , 2003, Progress in molecular and subcellular biology.
[55] R. Gainetdinov,et al. Plasma membrane monoamine transporters: structure, regulation and function , 2003, Nature Reviews Neuroscience.
[56] T. Sotnikova,et al. Monoamine transporter pharmacology and mutant mice. , 2002, Trends in pharmacological sciences.
[57] D. Mash,et al. Decreased expression of the transcription factor NURR1 in dopamine neurons of cocaine abusers , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[58] W. Gauderman. Sample size requirements for association studies of gene-gene interaction. , 2002, American journal of epidemiology.
[59] M. Bannon,et al. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders , 2001, European Neuropsychopharmacology.
[60] B. Dean,et al. Studies on dopaminergic and GABAergic markers in striatum reveals a decrease in the dopamine transporter in schizophrenia , 2001, Schizophrenia Research.
[61] R. Gur,et al. Striatal dopamine transporters and cognitive functioning in healthy men and women. , 2001, The American journal of psychiatry.
[62] J. Hietala,et al. PET studies of brain monoamine transporters. , 2000, Current pharmaceutical design.
[63] J. Krystal,et al. Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [123I]β-CIT , 2000, Biological Psychiatry.
[64] Xin Xu,et al. Implementing a unified approach to family‐based tests of association , 2000, Genetic epidemiology.
[65] A. Sampson,et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. , 1999, The American journal of psychiatry.
[66] P. Strange,et al. Comparison of the ability of dopamine receptor agonists to inhibit forskolin-stimulated adenosine 3'5'-cyclic monophosphate (cAMP) accumulation via D2L (long isoform) and D3 receptors expressed in Chinese hamster ovary (CHO) cells. , 1999, Biochemical pharmacology.
[67] J R O'Connell,et al. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.
[68] T. Kawarai,et al. Structure and organization of the gene encoding human dopamine transporter. , 1997, Gene.
[69] C. Schmauss,et al. Enhanced Cleavage of an Atypical Intron of Dopamine D3-Receptor Pre-mRNA in Chronic Schizophrenia , 1996, The Journal of Neuroscience.
[70] J. Kleinman,et al. Age-related changes in [3H]GBR 12935 binding site density in the prefrontal cortex of controls and schizophrenics , 1995, Biological Psychiatry.
[71] D. Curtis,et al. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci , 1995, Annals of human genetics.
[72] C. Halldin,et al. Pet study of [11C] β‐CIT binding to monoamine transporters in the monkey and human brain , 1994, Synapse.
[73] M. Caron,et al. Molecular characterization of the dopamine transporter. , 1993, Trends in pharmacological sciences.
[74] S. Amara,et al. Neurotransmitter transporters: recent progress. , 1993, Annual review of neuroscience.
[75] X Li,et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. , 1992, Genomics.
[76] G. Uhl,et al. A human dopamine transporter cDNA predicts reduced glycosylation, displays a novel repetitive element and provides racially-dimorphic TaqI RFLPs. , 1992, Brain research. Molecular brain research.
[77] M. Caron,et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. , 1992, Molecular pharmacology.
[78] P. Seeman,et al. Dopamine receptors and transporters in Parkinson's disease and schizophrenia , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[79] C. Tanaka,et al. [3H]GBR-12935 binding sites in human striatal membranes: binding characteristics and changes in parkinsonians and schizophrenics. , 1988, Japanese journal of pharmacology.
[80] P. Armitage. Tests for Linear Trends in Proportions and Frequencies , 1955 .